BACKGROUND: Increased attention has been directed toward the long-term health outcomes of survivors of childhood cancer. To facilitate such research, a multi-institutional consortium established the Childhood Cancer Survivor Study (CCSS), a large, diverse, and well-characterized cohort of 5-year survivors of childhood and adolescent cancer. PROCEDURE: Eligibility for the CCSS cohort included a selected group of cancer diagnoses prior to age 21 years between 1970-1986 and survival for at least 5 years. RESULTS: A total of 20,276 eligible subjects were identified from the 25 contributing institutions, of whom 15% are considered lost to follow-up. Currently, 14,054 subjects (69.3% of the eligible cohort) have participated by completing a 24-page baseline questionnaire. The distribution of first diagnoses includes leukemia (33%), lymphoma (21%), neuroblastoma (7%), CNS tumor (13%), bone tumor (8%), kidney tumor (9%), and soft-tissue sarcoma (9%). Abstraction of medical records for chemotherapy, radiation therapy, and surgical procedures has been successfully completed for 98% of study participants. Overall, 78% received radiotherapy and 73% chemotherapy. CONCLUSION: The CCSS represents the largest and most extensively characterized cohort of childhood and adolescent cancer survivors in North America. It serves as a resource for addressing important issues such as risk of second malignancies, endocrine and reproductive outcome, cardiopulmonary complications, and psychosocial implications, among this unique and ever-growing population. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND: Increased attention has been directed toward the long-term health outcomes of survivors of childhood cancer. To facilitate such research, a multi-institutional consortium established the Childhood Cancer Survivor Study (CCSS), a large, diverse, and well-characterized cohort of 5-year survivors of childhood and adolescent cancer. PROCEDURE: Eligibility for the CCSS cohort included a selected group of cancer diagnoses prior to age 21 years between 1970-1986 and survival for at least 5 years. RESULTS: A total of 20,276 eligible subjects were identified from the 25 contributing institutions, of whom 15% are considered lost to follow-up. Currently, 14,054 subjects (69.3% of the eligible cohort) have participated by completing a 24-page baseline questionnaire. The distribution of first diagnoses includes leukemia (33%), lymphoma (21%), neuroblastoma (7%), CNS tumor (13%), bone tumor (8%), kidney tumor (9%), and soft-tissue sarcoma (9%). Abstraction of medical records for chemotherapy, radiation therapy, and surgical procedures has been successfully completed for 98% of study participants. Overall, 78% received radiotherapy and 73% chemotherapy. CONCLUSION: The CCSS represents the largest and most extensively characterized cohort of childhood and adolescent cancer survivors in North America. It serves as a resource for addressing important issues such as risk of second malignancies, endocrine and reproductive outcome, cardiopulmonary complications, and psychosocial implications, among this unique and ever-growing population. Copyright 2002 Wiley-Liss, Inc.
Authors: Tara O Henderson; Kevin C Oeffinger; John Whitton; Wendy Leisenring; Joseph Neglia; Anna Meadows; Catherine Crotty; David T Rubin; Lisa Diller; Peter Inskip; Susan A Smith; Marilyn Stovall; Louis S Constine; Sue Hammond; Greg T Armstrong; Leslie L Robison; Paul C Nathan Journal: Ann Intern Med Date: 2012-06-05 Impact factor: 25.391
Authors: Lisa A Schwartz; Jun J Mao; Branlyn W Derosa; Jill P Ginsberg; Wendy L Hobbie; Claire A Carlson; Ifigenia D Mougianis; Sue K Ogle; Anne E Kazak Journal: J Am Board Fam Med Date: 2010 May-Jun Impact factor: 2.657
Authors: Rajaram Nagarajan; Anmmd Kamruzzaman; Kirsten K Ness; Victoria G Marchese; Charles Sklar; Ann Mertens; Yutaka Yasui; Leslie L Robison; Neyssa Marina Journal: Cancer Date: 2010-10-04 Impact factor: 6.860
Authors: Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger Journal: Ann Intern Med Date: 2010-10-05 Impact factor: 25.391
Authors: Michele Montgomery; Sujuan Huang; Cheryl L Cox; Wendy M Leisenring; Kevin C Oeffinger; Melissa M Hudson; Jill Ginsberg; Gregory T Armstrong; Leslie L Robison; Kirsten K Ness Journal: J Cancer Surviv Date: 2010-10-05 Impact factor: 4.442
Authors: Melissa M Hudson; Wendy Leisenring; Kayla K Stratton; Nina Tinner; Brenda D Steen; Susan Ogg; Linda Barnes; Kevin C Oeffinger; Leslie L Robison; Cheryl L Cox Journal: J Clin Oncol Date: 2014-11-03 Impact factor: 44.544
Authors: Germán Velez-Florez; María Camila Velez-Florez; Jose Oscar Mantilla-Rivas; Liliana Patarroyo-Rodríguez; Rodrigo Borrero-León; Santiago Rodríguez-León Journal: Curr Psychiatry Rep Date: 2018-07-21 Impact factor: 5.285
Authors: Kevin C Oeffinger; Jennifer S Ford; Chaya S Moskowitz; Lisa R Diller; Melissa M Hudson; Joanne F Chou; Stephanie M Smith; Ann C Mertens; Tara O Henderson; Debra L Friedman; Wendy M Leisenring; Leslie L Robison Journal: JAMA Date: 2009-01-28 Impact factor: 56.272
Authors: Susan Ogg; James L Klosky; Wassim Chemaitilly; Deo Kumar Srivastava; Mingjuan Wang; Ginger Carney; Rohit Ojha; Leslie L Robison; Cheryl L Cox; Melissa M Hudson Journal: J Cancer Surviv Date: 2020-04-14 Impact factor: 4.442
Authors: Kris Ann P Schultz; Lu Chen; Zhengjia Chen; Toana Kawashima; Kevin C Oeffinger; William G Woods; H Stacy Nicholson; Joseph P Neglia Journal: Pediatr Blood Cancer Date: 2013-11-27 Impact factor: 3.167